-
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients.
-
Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential in combination settings in mBC, along with updates from the
elacestrant clinical development program, including its potential role as a monotherapy option in adjuvant breast cancer.
- Stemline's partner, Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in myelofibrosis
"FOR MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY"
FLORENCE, Italy and NEW YORK, May 25, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and tagraxofusp will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
